Hosted on MSN

A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
EurekAlert!

First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer

SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone ...
Healio

Biomarker a ‘true milestone’ in guiding hormone therapy for recurrent prostate cancer

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...
National Geographic news

How breast cancer research is helping prostate cancer patients

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Researchers identify new target to prevent aggressive form of prostate cancer

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...